Samiec M et al. |
Trichostatin A-mediated epigenetic transformation of adult bone marrow-derived mesenchymal stem cells biases the in vitro developmental capability, quality, and pluripotency extent of porcine cloned embryos. |
2015 |
Biomed Res Int |
pmid:25866813
|
Hou H et al. |
Influence of intra-articular administration of trichostatin a on autologous osteochondral transplantation in a rabbit model. |
2015 |
Biomed Res Int |
pmid:25866784
|
Chan ST et al. |
Oral and intraperitoneal administration of quercetin decreased lymphocyte DNA damage and plasma lipid peroxidation induced by TSA in vivo. |
2014 |
Biomed Res Int |
pmid:24868531
|
Florea AM |
DNA methylation pyrosequencing assay is applicable for the assessment of epigenetic active environmental or clinical relevant chemicals. |
2013 |
Biomed Res Int |
pmid:24093099
|
Ilicic M et al. |
Modulation of Progesterone Receptor Isoform Expression in Pregnant Human Myometrium. |
2017 |
Biomed Res Int |
pmid:28540297
|
Piotrowska H and Jagodzinski PP |
Trichostatin A, sodium butyrate, and 5-aza-2'-deoxycytidine alter the expression of glucocorticoid receptor alpha and beta isoforms in Hut-78 T- and Raji B-lymphoma cell lines. |
2007 |
Biomed. Pharmacother. |
pmid:17498915
|
Drzewiecka H and Jagodzinski PP |
Trichostatin A reduced phospholipase C gamma-1 transcript and protein contents in MCF-7 breast cancer cells. |
2012 |
Biomed. Pharmacother. |
pmid:22257695
|
Cheng SP et al. |
Regulation of leptin receptor expression in human papillary thyroid cancer cells. |
2012 |
Biomed. Pharmacother. |
pmid:22560341
|
Åuczak MW and JagodziÅ„ski PP |
Trichostatin A down-regulates CYP19 transcript and protein levels in MCF-7 breast cancer cells. |
2009 |
Biomed. Pharmacother. |
pmid:18602794
|
Feng W et al. |
Combination of HDAC inhibitor TSA and silibinin induces cell cycle arrest and apoptosis by targeting survivin and cyclinB1/Cdk1 in pancreatic cancer cells. |
2015 |
Biomed. Pharmacother. |
pmid:26349994
|
Sobolewski C et al. |
Histone Deacetylase Inhibitors Activate Tristetraprolin Expression through Induction of Early Growth Response Protein 1 (EGR1) in Colorectal Cancer Cells. |
2015 |
Biomolecules |
pmid:26343742
|
McCulloch MW et al. |
Psammaplin A as a general activator of cell-based signaling assays via HDAC inhibition and studies on some bromotyrosine derivatives. |
2009 |
Bioorg. Med. Chem. |
pmid:19022675
|
Fu J et al. |
Discovery of 1H-benzo[d][1,2,3]triazol-1-yl 3,4,5-trimethoxybenzoate as a potential antiproliferative agent by inhibiting histone deacetylase. |
2010 |
Bioorg. Med. Chem. |
pmid:21067930
|
Saha A et al. |
Synthesis and biological evaluation of a targeted DNA-binding transcriptional activator with HDAC8 inhibitory activity. |
2013 |
Bioorg. Med. Chem. |
pmid:23719282
|
Schäfer S et al. |
Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs). |
2008 |
Bioorg. Med. Chem. |
pmid:18054239
|
Terracciano S et al. |
Synthesis and biological activity of cyclotetrapeptide analogues of the natural HDAC inhibitor FR235222. |
2010 |
Bioorg. Med. Chem. |
pmid:20381359
|
Chen PC et al. |
Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group. |
2008 |
Bioorg. Med. Chem. |
pmid:18397827
|
Whitehead L et al. |
Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors. |
2011 |
Bioorg. Med. Chem. |
pmid:21723733
|
Feng T et al. |
Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2). |
2013 |
Bioorg. Med. Chem. |
pmid:23820574
|
Mukherjee P et al. |
Structural insights into the Plasmodium falciparum histone deacetylase 1 (PfHDAC-1): A novel target for the development of antimalarial therapy. |
2008 |
Bioorg. Med. Chem. |
pmid:18362073
|
Di Micco S et al. |
Structural basis for the design and synthesis of selective HDAC inhibitors. |
2013 |
Bioorg. Med. Chem. |
pmid:23693069
|
Patil V et al. |
Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group. |
2010 |
Bioorg. Med. Chem. |
pmid:19914074
|
Nishino N et al. |
Interaction of aliphatic cap group in inhibition of histone deacetylases by cyclic tetrapeptides. |
2008 |
Bioorg. Med. Chem. |
pmid:17900911
|
Shivashimpi GM et al. |
Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. |
2007 |
Bioorg. Med. Chem. |
pmid:17881232
|
Estiu G et al. |
On the inhibition of histone deacetylase 8. |
2010 |
Bioorg. Med. Chem. |
pmid:20472442
|
Kaldre D et al. |
Optimization of histone deacetylase inhibitor activity in non-secosteroidal vitamin D-receptor agonist hybrids. |
2015 |
Bioorg. Med. Chem. |
pmid:26048026
|
Kiyokawa S et al. |
New orally bioavailable 2-aminobenzamide-type histone deacetylase inhibitor possessing a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group. |
2010 |
Bioorg. Med. Chem. |
pmid:20452226
|
Giannini G et al. |
N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. |
2009 |
Bioorg. Med. Chem. Lett. |
pmid:19285395
|
Lee S et al. |
Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. |
2007 |
Bioorg. Med. Chem. Lett. |
pmid:17588744
|
Nishino N et al. |
Synthesis and histone deacetylase inhibitory activity of cyclic tetrapeptides containing a retrohydroxamate as zinc ligand. |
2004 |
Bioorg. Med. Chem. Lett. |
pmid:15109626
|
Marson CM et al. |
Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. |
2004 |
Bioorg. Med. Chem. Lett. |
pmid:15109636
|
Vaisburg A et al. |
(2-amino-phenyl)-amides of omega-substituted alkanoic acids as new histone deacetylase inhibitors. |
2004 |
Bioorg. Med. Chem. Lett. |
pmid:14684344
|
Hoque MA et al. |
Cyclic tetrapeptides with thioacetate tails or intramolecular disulfide bridge as potent inhibitors of histone deacetylases. |
2012 |
Bioorg. Med. Chem. Lett. |
pmid:23021104
|
Krennhrubec K et al. |
Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. |
2007 |
Bioorg. Med. Chem. Lett. |
pmid:17346959
|
Rajak H et al. |
2,5-Disubstituted-1,3,4-oxadiazoles/thiadiazole as surface recognition moiety: design and synthesis of novel hydroxamic acid based histone deacetylase inhibitors. |
2011 |
Bioorg. Med. Chem. Lett. |
pmid:21875796
|
Vaidya AS et al. |
Novel histone deacetylase 8 ligands without a zinc chelating group: exploring an 'upside-down' binding pose. |
2012 |
Bioorg. Med. Chem. Lett. |
pmid:23010266
|
Loudni L et al. |
Design, synthesis and biological evaluation of 1,4-benzodiazepine-2,5-dione-based HDAC inhibitors. |
2007 |
Bioorg. Med. Chem. Lett. |
pmid:17624773
|
Wang DF et al. |
QSAR studies of PC-3 cell line inhibition activity of TSA and SAHA-like hydroxamic acids. |
2004 |
Bioorg. Med. Chem. Lett. |
pmid:14741273
|
Hirata Y et al. |
Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain. |
2012 |
Bioorg. Med. Chem. Lett. |
pmid:22321215
|
Desai D et al. |
SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors. |
2010 |
Bioorg. Med. Chem. Lett. |
pmid:20167479
|
Jose B et al. |
Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones. |
2004 |
Bioorg. Med. Chem. Lett. |
pmid:15454224
|
Liao V et al. |
Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects. |
2012 |
Bioorg. Med. Chem. Lett. |
pmid:22932316
|
Pabba C et al. |
Design and synthesis of aryl ether and sulfone hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. |
2011 |
Bioorg. Med. Chem. Lett. |
pmid:21109435
|
Smil DV et al. |
Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors. |
2009 |
Bioorg. Med. Chem. Lett. |
pmid:19111466
|
Islam NM et al. |
Bicyclic peptides as potent inhibitors of histone deacetylases: optimization of alkyl loop length. |
2010 |
Bioorg. Med. Chem. Lett. |
pmid:20045316
|
Riester D et al. |
Non-isotopic dual parameter competition assay suitable for high-throughput screening of histone deacetylases. |
2009 |
Bioorg. Med. Chem. Lett. |
pmid:19457659
|
Gupta PK et al. |
Inhibitors selective for HDAC6 in enzymes and cells. |
2010 |
Bioorg. Med. Chem. Lett. |
pmid:20947351
|
Shinji C et al. |
Design and synthesis of phthalimide-type histone deacetylase inhibitors. |
2005 |
Bioorg. Med. Chem. Lett. |
pmid:16137884
|
Uesato S et al. |
Novel histone deacetylase inhibitors: N-hydroxycarboxamides possessing a terminal bicyclic aryl group. |
2002 |
Bioorg. Med. Chem. Lett. |
pmid:11992774
|
Hooven LA et al. |
Effects of suberoylanilide hydroxamic acid and trichostatin A on induction of cytochrome P450 enzymes and benzo[a]pyrene DNA adduct formation in human cells. |
2005 |
Bioorg. Med. Chem. Lett. |
pmid:15713371
|
Chen B et al. |
Chemistry and biology of mercaptoacetamides as novel histone deacetylase inhibitors. |
2005 |
Bioorg. Med. Chem. Lett. |
pmid:15713393
|
Yu D et al. |
Clonal Rett Syndrome cell lines to test compounds for activation of wild-type MeCP2 expression. |
2011 |
Bioorg. Med. Chem. Lett. |
pmid:21840716
|
Vasudevan A et al. |
Heterocyclic ketones as inhibitors of histone deacetylase. |
2003 |
Bioorg. Med. Chem. Lett. |
pmid:14592473
|
Choi E et al. |
Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors. |
2011 |
Bioorg. Med. Chem. Lett. |
pmid:21256006
|
Nakao Y et al. |
Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells. |
2008 |
Bioorg. Med. Chem. Lett. |
pmid:18397826
|
Mazitschek R et al. |
Development of a fluorescence polarization based assay for histone deacetylase ligand discovery. |
2008 |
Bioorg. Med. Chem. Lett. |
pmid:18430569
|
Charrier C et al. |
Synthesis of rigid trichostatin A analogs as HDAC inhibitors. |
2006 |
Bioorg. Med. Chem. Lett. |
pmid:16904890
|
Charrier C et al. |
Antiproliferative activities of a library of hybrids between indanones and HDAC inhibitor SAHA and MS-275 analogues. |
2007 |
Bioorg. Med. Chem. Lett. |
pmid:17897824
|
Van Ommeslaeghe K et al. |
Amide analogues of TSA: synthesis, binding mode analysis and HDAC inhibition. |
2003 |
Bioorg. Med. Chem. Lett. |
pmid:12749885
|
Suzuki T et al. |
Identification of a potent and stable antiproliferative agent by the prodrug formation of a thiolate histone deacetylase inhibitor. |
2007 |
Bioorg. Med. Chem. Lett. |
pmid:17257837
|
Lavoie R et al. |
Design and synthesis of a novel class of histone deacetylase inhibitors. |
2001 |
Bioorg. Med. Chem. Lett. |
pmid:11597413
|
Tobias CA et al. |
Improved recombinant retroviral titers utilizing trichostatin A. |
2000 |
BioTechniques |
pmid:11056820
|
Seo H et al. |
Modulation of immunoglobulin gene conversion in chicken DT40 by enhancing histone acetylation, and its application to antibody engineering. |
2007 |
Biotechnol. Genet. Eng. Rev. |
pmid:18059633
|
Kalaiarasi A et al. |
Copper oxide nanoparticles induce anticancer activity in A549 lung cancer cells by inhibition of histone deacetylase. |
2018 |
Biotechnol. Lett. |
pmid:29116558
|
Liu X et al. |
The improvement of adenovirus vector production by increased expression of coxsackie adenovirus receptor. |
2009 |
Biotechnol. Lett. |
pmid:19330491
|
Kim HJ et al. |
Enhancement of human mesenchymal stem cell differentiation by combination treatment with 5-azacytidine and trichostatin A. |
2016 |
Biotechnol. Lett. |
pmid:26341652
|
Menegola E et al. |
Inhibition of histone deacetylase activity on specific embryonic tissues as a new mechanism for teratogenicity. |
2005 |
Birth Defects Res. B Dev. Reprod. Toxicol. |
pmid:16193500
|
Rahman MM et al. |
Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. |
2003 |
Blood |
pmid:12511413
|
Zhou DC et al. |
Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. |
2002 |
Blood |
pmid:11830487
|
Milhem M et al. |
Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A. |
2004 |
Blood |
pmid:14976039
|
Cao H et al. |
Induction of human gamma globin gene expression by histone deacetylase inhibitors. |
2004 |
Blood |
pmid:12920038
|
Hebbel RP et al. |
The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice. |
2010 |
Blood |
pmid:20053759
|
Sadoul K et al. |
HDAC6 controls the kinetics of platelet activation. |
2012 |
Blood |
pmid:22955928
|
Hambach L et al. |
Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy. |
2009 |
Blood |
pmid:19096014
|
Petti MC et al. |
Complete remission through blast cell differentiation in PLZF/RARalpha-positive acute promyelocytic leukemia: in vitro and in vivo studies. |
2002 |
Blood |
pmid:12130525
|
Araki H et al. |
Chromatin-modifying agents permit human hematopoietic stem cells to undergo multiple cell divisions while retaining their repopulating potential. |
2007 |
Blood |
pmid:17185465
|
Chaurasia P et al. |
Chromatin-modifying agents promote the ex vivo production of functional human erythroid progenitor cells. |
2011 |
Blood |
pmid:21355088
|
Jamaluddin MD et al. |
Homocysteine inhibits endothelial cell growth via DNA hypomethylation of the cyclin A gene. |
2007 |
Blood |
pmid:17698632
|
Wang X et al. |
Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells. |
2010 |
Blood |
pmid:20858855
|
Witt O et al. |
Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. |
2003 |
Blood |
pmid:12393499
|
Smith RD et al. |
Quantitative PCR analysis of HbF inducers in primary human adult erythroid cells. |
2000 |
Blood |
pmid:10648397
|
Ishiguro K and Sartorelli AC |
Coinduction of embryonic and adult-type globin mRNAs by sodium butyrate and trichostatin A in two murine interleukin-3-dependent bone marrow-derived cell lines. |
1998 |
Blood |
pmid:9834245
|
Li X et al. |
Mta3-NuRD complex is a master regulator for initiation of primitive hematopoiesis in vertebrate embryos. |
2009 |
Blood |
pmid:19864643
|
Gao C et al. |
Targeting transcription factor SALL4 in acute myeloid leukemia by interrupting its interaction with an epigenetic complex. |
2013 |
Blood |
pmid:23287862
|
Chen Z et al. |
BCL11A represses HBG transcription in K562 cells. |
2009 Mar-Apr |
Blood Cells Mol. Dis. |
pmid:19153051
|
Swank RA et al. |
The histone deacetylase inhibitor, trichostatin A, reactivates the developmentally silenced gamma globin expression in somatic cell hybrids and induces gamma gene expression in adult BFUe cultures. |
2003 May-Jun |
Blood Cells Mol. Dis. |
pmid:12737942
|
Xu ZM et al. |
The novel gene LRP15 is regulated by DNA methylation and confers increased efficiency of DNA repair of ultraviolet-induced DNA damage. |
2008 |
BMB Rep |
pmid:18377727
|
Viñuelas J et al. |
Quantifying the contribution of chromatin dynamics to stochastic gene expression reveals long, locus-dependent periods between transcriptional bursts. |
2013 |
BMC Biol. |
pmid:23442824
|
Nordström L et al. |
DNA methylation and histone modifications regulate SOX11 expression in lymphoid and solid cancer cells. |
2015 |
BMC Cancer |
pmid:25880212
|
Mossman D et al. |
Demethylation by 5-aza-2'-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists. |
2010 |
BMC Cancer |
pmid:20618997
|
Wu Y et al. |
Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation. |
2010 |
BMC Cancer |
pmid:20132554
|
Acun T et al. |
SIP1 is downregulated in hepatocellular carcinoma by promoter hypermethylation. |
2011 |
BMC Cancer |
pmid:21645397
|
DÃaz-Núñez M et al. |
Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity. |
2016 |
BMC Cancer |
pmid:27549189
|
Mazières J et al. |
Epigenetic regulation of RhoB loss of expression in lung cancer. |
2007 |
BMC Cancer |
pmid:18047684
|
Arce L et al. |
Groucho binds two conserved regions of LEF-1 for HDAC-dependent repression. |
2009 |
BMC Cancer |
pmid:19460168
|
Tombolan L et al. |
Global DNA methylation profiling uncovers distinct methylation patterns of protocadherin alpha4 in metastatic and non-metastatic rhabdomyosarcoma. |
2016 |
BMC Cancer |
pmid:27842508
|
Dávalos-Salas M et al. |
Gain of DNA methylation is enhanced in the absence of CTCF at the human retinoblastoma gene promoter. |
2011 |
BMC Cancer |
pmid:21663659
|
Kim TW et al. |
Nuclear-encoded mitochondrial MTO1 and MRPL41 are regulated in an opposite epigenetic mode based on estrogen receptor status in breast cancer. |
2013 |
BMC Cancer |
pmid:24160266
|
Mühlethaler-Mottet A et al. |
Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio. |
2006 |
BMC Cancer |
pmid:16930472
|
Puppin C et al. |
HEX expression and localization in normal mammary gland and breast carcinoma. |
2006 |
BMC Cancer |
pmid:16854221
|